Stock Market Reviews

MLTX (MoonLake Immunotherapeutics) News

Get the latest news, insights, and market updates on MLTX (MoonLake Immunotherapeutics). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• MoonLake Immunotherapeutics (MLTX) Q2 Net Loss Widens to US$55 Million
  During the last quarter, MoonLake Immunotherapeutics (MLTX) reported a significant increase in net losses, with a net loss of $55 million for the second quarter, up from $24 million in the same period in 2024. This coincided with a broader market trend where tech stocks led the Nasdaq to record highs, and the S&P 500 saw growth. Despite the increase in losses, MoonLake's stock price rose by 19.02% over the quarter, moving in line with the overall market's upward trend of 19% over the past...
  Sep 13, 2025 - $MLTX
• Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)
  MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 21, Leerink Partners analyst Thomas Smith reiterated a Buy rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a price target of $73. Smith highlighted the potential of the company’s Sonelokimab in treating moderate-to-severe hidradenitis suppurativa. […]
  Sep 10, 2025 - $MLTX
• 2 Small-Cap Biotech Stocks Well Positioned for a Breakout
  Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.
  Aug 27, 2025 - $MLTX
• MoonLake Immunotherapeutics (MLTX): A Bull Case Theory
  We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX. MoonLake Immunotherapeutics’s share was trading at $51.89 as of August 7th. MoonLake Immunotherapeutics (MLTX) represents a high-upside, asymmetric biotech opportunity ahead of its critical September 2025 Phase 3 readout (VELA) in hidradenitis suppurativa […]
  Aug 17, 2025 - $MLTX